Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.critrevonc.2020.102991 http://scihub22266oqcxt.onion/10.1016/j.critrevonc.2020.102991 32544802!7239789!32544802     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Crit+Rev+Oncol+Hematol 2020 ; 152 (ä): 102991 Nephropedia Template TP {{tp|p=32544802|t=2020. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature |pdf=|usr=}}{{32544802}} gab.com Text COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature JO: Crit Rev Oncol Hematol http://www.kidney.de/pget.php?&tw=1&pmid=32544802 #FOAvip BACKGROUND: It is reasonable to think that cancer patients undergoing chemotherapy, targeted therapy or immunotherapy could have a more aggressive course if positive for Coronavirus disease CoV-2 (COVID- 19). METHODS: We conducted a literature review on https://www.ncbi.nlm.nih.gov/pubmed/, https://scholar.google.com, www.arxiv.org, www.biorxiv.org, of all articles published using the keywords COVID-19 therapy or treatment and cancer until May 2, 2020. A total of 205 articles were identified and 53 were included in this review. RESULTS: We describe the ongoing COVID-19 therapies that should be known by oncologists and highlight the potential interactions with antineoplastic drugs, commonly used in clinical practice. The main drug interactions were found with tocilizumab, ruxolitinib and colchicine. CONCLUSIONS: The literature provides an inconclusive picture on potential preferred treatments for COVID-19 and their interactions with antineoplastic agents. Future clinical trials are needed to better understand the interactions between different drugs in the context of COVID-19 pandemic. Twit Text FOAVip COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature ????Crit Rev Oncol Hematol http://www.kidney.de/pget.php?&tw=1&pmid=32544802 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32544802 #FOAvip English Wikipedia <ref>{{Cite pmid|32544802}}</ref> COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature #MMPMID32544802 Di Lorenzo G; Di Trolio R; Kozlakidis Z; Busto G; Ingenito C; Buonerba L; Ferrara C; Libroia A; Ragone G; Ioio CD; Savastano B; Polverino M; De Falco F; Iaccarino S; Leo E Crit Rev Oncol Hematol 2020[Aug]; 152 (ä): 102991 PMID32544802show ga BACKGROUND: It is reasonable to think that cancer patients undergoing chemotherapy, targeted therapy or immunotherapy could have a more aggressive course if positive for Coronavirus disease CoV-2 (COVID- 19). METHODS: We conducted a literature review on https://www.ncbi.nlm.nih.gov/pubmed/, https://scholar.google.com, www.arxiv.org, www.biorxiv.org, of all articles published using the keywords COVID-19 therapy or treatment and cancer until May 2, 2020. A total of 205 articles were identified and 53 were included in this review. RESULTS: We describe the ongoing COVID-19 therapies that should be known by oncologists and highlight the potential interactions with antineoplastic drugs, commonly used in clinical practice. The main drug interactions were found with tocilizumab, ruxolitinib and colchicine. CONCLUSIONS: The literature provides an inconclusive picture on potential preferred treatments for COVID-19 and their interactions with antineoplastic agents. Future clinical trials are needed to better understand the interactions between different drugs in the context of COVID-19 pandemic. |*Coronavirus Infections/drug therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy[MESH] |Antineoplastic Agents/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Humans[MESH]COVID 19 therapies and anti-cancer drugs: A systematic review of recen(epmc).pdf DeepDyve Pubget Overpricing